Drug development: More science, more education

British Journal of Clinical Pharmacology

Volumn 59, Issue 4, 2005, Pages 377-378

  Aronson, J K ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG RESEARCH; EDITORIAL; EDUCATION PROGRAM; FOOD AND DRUG ADMINISTRATION; MEDICAL EDUCATION; PRIORITY JOURNAL;

DRUG APPROVAL; DRUG DESIGN; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 17144368420     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0306-5251.2005.02420.x     Document Type: Editorial

References (8)

1. Sheiner L. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-91.
2. Aronson JK. Editors' view. Features of this month's Journal. Br J Clin Pharmacol 2003; 56: 141-2.
3. Food and Drug Administration. Challenge and Opportunity on the Critical Path to New Medical Products. Revised version, http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html (accessed 28 February, 2005).
4. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. Br Med J 2003; 327: 1222-5.
5. Motola D, De Ponti F, Rossi P, Martini N, Montanaro N. Therapeutic innovation in the European Union: Analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2005 59: 475-8.
6. Baber NS, Ritter JM, Aronson JK. Medicines regulation and clinical pharmacology. Br J Clin Pharmacol 2004; 58: 569-70.
7. Tucker C. Pharmacogenetics - expectations and reality. Br Med J 2004; 329: 4-6.
8. Stanley AC, Jackson D, Barnett DB. The teaching of drug development to medical students: collaboration between the pharmaceutical industry and medical school. Br J Clin Pharmacol 2005; 59: 464-74.